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Abstract
By using structure-based drug design and isosteric replacement, diarylaniline and 1,5-
diarylbenzene-1,2-diamine derivatives were synthesized and evaluated against wild type HIV-1
and drug-resistant viral strains, resulting in the discovery of diarylaniline derivatives as a distinct
class of next-generation HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) agents.
The most promising compound 37 showed significant EC50 values of 0.003-0.032 μM against
HIV-1 wild-type strains and of 0.005-0.604 μM against several drug-resistant strains. Current
results also revealed important structure-activity relationship (SAR) conclusions for diarylanilines
and strongly support our hypothesis that an NH2 group on the central benzene ring ortho to the
aniline moiety is crucial for interaction with K101 of the NNRTI binding site in HIV-1 RT, likely
by forming H-bonds with K101. Furthermore, molecular modeling studies with molecular
mechanism/general born surface area (MM/GBSA) technology demonstrated the rationality of our
hypothesis.
Introduction
According to UNAIDS statistics, more than 60 million people worldwide have been infected
by the human immunodeficiency virus (HIV), and about 25 million patients have died of
AIDS. In the absence of an effective vaccine, there is a need to develop effective anti-HIV
therapeutics to prolong the lives of HIV-infected individuals. Thus far, more than 20 anti-
HIV drugs have been approved by the U.S. FDA (www.fda.gov/oashi/aids/virals.html)
including reverse transcriptase inhibitors (RTIs), protease inhibitors (PIs), fusion inhibitors,
integrase inhibitors, and entry inhibitors (CCR5 co-receptor antagonist). Highly active
antiretroviral therapy (HAART), which uses a combination of three to four drugs, can
significantly reduce the morbidity and mortality of HIV-1 infected patients. However, as a
result of emerging drug-resistant HIV mutants, increasing numbers of HIV-infected patients
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fail to respond to HAART. Thus, the development of new anti-HIV drugs is urgently
required.
To address this need, we have synthesized compounds targeting HIV-1 reverse transcriptase
(RT), one of the most important enzymes in the HIV-1 life cycle. It has two known drug-
target sites, the substrate binding site and an allosteric site, which is distinct from, but
closely located to, the substrate binding site.1,2 Specifically, we focused on non-nucleoside
reverse transcriptase inhibitors (NNRTIs) that interact with the allosteric binding site, a
highly hydrophobic cavity, in a noncompetitive manner to cause distortion of the three-
dimensional structure of the enzyme and thus inhibit RT catalytic function. NNRTIs
currently approved for AIDS therapy include delavirdine (1), nevirapine (2), efavirenz (3),
and etravirine (TMC125, 4) (Figure 1).3 In general, NNRTIs exhibit high inhibitory potency
and low toxicity, but drug resistance to NNRTIs has emerged rapidly as a result of mutations
in amino acid residues that are in or surround the NNRTI binding site. Compound 4 is the
most recently approved NNRTI and is active against many drug-resistant HIV-1 strains. The
related riplivirine (TMC278, 5)4 is now undergoing phase III clinical trials as a promising
new drug candidate. Compounds 4, 5, and TMC120 (6),5 a prior clinical candidate, belong
to the diarylpyrimidine (DAPY) family (Fig 1), and all are very potent against wild-type and
many drug-resistant HIV-1 strains with nanomolar EC50 values. They have excellent
pharmacological profiles, which has encouraged more research to explore next-generation
NNRTI agents.6-8 In this study, we used isosteric replacements to synthesize new NNRTIs,
and consequently discovered a series of diarylaniline compounds with high potency against
both wild-type and RT-resistant viral strains.
Design
Prior studies4,9 on DAPY derivatives have resulted in informative SAR conclusions,
including (1) a “U” or horseshoe binding conformation in contrast to the typical butterfly-
like binding shape of 1-3, (2) a proper positioning of two phenyl rings in the eastern and
western wings of the NNRT binding pockets, (3) a para-substituted aniline moiety in the
eastern wing, and (4) two hydrogen bonds between K101 of HIV-1 RT to the NH linker and
the nitrogen atom on the pyrimidine ring.10 Crystal structures of complexes K103N HIV-1
RT/4 [protein data base (PDB) code: 1sv5], HIV-1 RT/5 (PDB: 2zd1), K103N/Y181C
HIV-1 RT/5 (PDB: 3bgr) and HIV-1 RT/6 (PDB: 1s6q)11,12 further indicate that two
flexible linkers between rings allow the inhibitors to adopt bound conformations with either
wild-type or mutant HIV-1 RT, resulting in high potency against both wild-type and a wide
range of drug-resistant mutant HIV-1 RT. Therefore, the molecular flexibility of DAPY
compounds is considered to be very crucial for next-generation NNRTI drugs.
Based on these SAR data, our strategy was to synthesize new compounds by using isosteric
replacement in the central B-ring of DAPY compounds. Unlike the reported DAPY
derivatives,13-15 the new analogs designed in this study (Figure 2) have a central benzene
ring rather than the pyrimidine in DAPY compounds. The new compounds also retain two
phenyl rings in the eastern and western wings, but have different para-substituents from the
DAPY compounds. Because the presence of a central benzene ring does not change
molecular topology and flexibility, these new compounds are expected to have similar
binding orientations and conformations to those of DAPYs. However, they will lose the H-
bond between K101 and the nitrogen on the pyrimidine ring of DAPY family compounds.10
To compensate for this loss, we introduced a nitro or amino group (R4) on the central
benzene ring at the ortho-position to the aniline ring to serve as H-bond acceptor or donor,
respectively, and to interact with K101 on the binding site. Furthermore, we investigated
how an additional nitro or amino group (R2) on the opposite side of the central phenyl ring
would affect anti-HIV activity.
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All target compounds were synthesized via the short routes detailed in Schemes 1 and 2. The
starting material, 1,3-dichloro-4,6-dinitrobenzene or 2,4-dichloro-1-nitrobenzene, is
inexpensive and commercially available. The dichloronitrobenzene was reacted with a para-
substituted aniline in a 1:1.1 molar ratio in DMF at room temperature for less than 40 min in
the presence of triethylamine to provide corresponding N-aryl-5-chloro- 2,4-dinitroanilines
(7-11) or in the presence of potassium tert-butoxide (t-BuOK) to provide corresponding N-
aryl-5-chloro-2-nitroanilines (12). The nucleophilic substitution took place between the
aromatic amine and the chloride at the ortho-position to the nitro group in 71-94% yields.
Compounds 7-12 were then coupled with a substituted phenol by using microwave
irradiation in DMF (or DMSO) in the presence of potassium carbonate with stirring at 190
°C for 15 min to afford diaryl-dinitroanilines (13-23) and diaryl-mononitroanilines (24-28).
16, 17 Some compounds could also be prepared by the traditional method of heating at 130
°C for 5 h with yields ranging from 74-94%. As shown in Scheme 2, di-nitro (19-22) and
mono-nitro (24, 26-27) compounds were reduced completely by using hydrazine hydrate in
isopropanol in the presence of FeCl3·6H2O and activated carbon at reflux for 20-30 min to
prepare corresponding di-amino (32-35) or mono-amino (29-31) compounds, respectively,
in 83-95% yields. Alternatively, 19, 21, and 22 were reduced selectively by formic acid in
the presence of Pd-C (10%) and triethylamine in acetonitrile under reflux for 1 h to give
corresponding 1,5-diaryl-4-nitrobenzene-1,2-diamines 36-38, respectively.18 Next, 37 was
reacted with triethyl orthoformate under acidic conditions to provide the benzoimidazole
product 39. This reaction validated that the nitro group ortho to the NH-linked aniline was
reduced selectively in the prior step. Furthermore, active compound 36 was converted to
hydrochloride salt 40 (shown in Scheme 2) in acetone to investigate the effect of improved
molecular water-solubility on anti-HIV activity.
Results and Discussion
All target compounds were first tested against wild-type HIV-1 (IIIB strain) replication in
the H9 cell line, and the results are summarized in Table 1. The most potent compound 37
had an EC50 value of 0.003 μM and an extremely high selective index (SI) of 20,887 in this
initial assay. Compound 36 and its hydrochloride salt 40 were also very potent with EC50
values of 0.016 μM and 0.012 μM, respectively; SI values of both compounds were >2800.
Other active compounds 27, 29-31, 34-35, and 38 had EC50 values ranging between 0.030–
0.073 μM and SI values between 520–1698. In addition, compounds 19, 20, 22, 24, 26 and
32 showed potency at the sub-micromolar level and had a SI range of >113–313. These
promising results demonstrated that the isosteric replacement of carbon for nitrogen in the
central B-ring of DAPY compounds was successful and resulted in the discovery of a series
of 1,5-diarylbenzene-1,2-diamine analogs as potent NNRTI agents.
Some SAR results for this compound series can be concluded from the data in Table 1. 1)
For the para-substituent on the A-ring (R1 moiety), the cyano (CN) group appears to be
necessary at this position for increased anti-HIV activity. Among compounds 13-19, only 19
(R1 = CN) exhibited high anti-HIV-1 activity with an EC50 value of 0.172 μM and SI of
>301, while 13-18 (R1 = MeO, Me, Cl, or NO2) were much less active (EC50 >2.99 μM) or
inactive. Except for compounds 21, 23, 28, and 33, all the other compounds containing the
active p-cyanoanilino A-ring (19-20, 22, 24-27, 29-32, 34-38, and 40) exhibited potent
inhibitory activity against wild-type HIV-1 replication. 2) The presence of NH2 (R4 moiety)
on the central B-ring ortho to anilino A-ring position in 29-38 and 40 generally enhanced the
anti-HIV-1 activity of the analogs (EC50: 0.003-0.161 μM), except for 33. The NH2-
substituted compounds (32, 34, 35, 29, 30, 31) were as or more potent than the
corresponding NO2-substituted compounds (19, 21, 22, 24, 26, 27), respectively. This result
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is consistent with that in our previous report on diarylpyridine compounds,19 and therefore,
supports our hypothesis that an amino group at the R4 position of the central B-ring is
crucial for interaction with K101 on the NNRTI binding site and can form additional H-
bonds to the protein. 3) On the central B-ring ortho to the phenoxy C-ring position (R2
substituent), NO2 moiety (36-38) is more favorable compared with H (29-31) or NH2 (32,
34-35) for achieving high anti-HIV-1 potency. 4) Br, CN, and CH3 para-substituent (R3
moiety) on the C-ring showed better anti-HIV activity, but CHO and H (23, 28, and 33) did
not. In addition, compound 40, the hydrochloride salt of 36, displayed more potent
inhibitory activity than 36, suggesting a possibility to improve water-solubility in active
compounds.
The most active compounds 34, 36, and 37 were further evaluated in comparison with the
anti-HIV-1 NNRTI drugs 1 and 4 against wild-type HIV-1 and several RTI-resistant viral
strains in the MT-2 cell line. These data are summarized in Tables 2 and 3. As shown in
Table 2, we found that both 37 and 36 showed better EC50 values (0.005 and 0.008 μM,
respectively) against HIV-1IIIB wild-type virus than 1. While drug 1 lost its antiviral
replication activity completely against multi-RTI-resistant mutants, compounds 34, 36, and
37 retained their high potency towards these viruses. Impressively, compound 37 still
showed the most potent EC50 value of 0.005 μM against multi-RTI-resistant mutants
8605MR and 6005MR. Compound 36 also was highly active against these mutants, with
similar or slightly lower potency than 37. Compound 37 kept some of its antiviral activity
against NNRTI-resistant mutant Y181C and A17 (Y181C/K103N) with EC50 values of
0.504 and 0.231 μM, respectively, while 1 completely lost its potency. Compound 36 also
showed moderate inhibition activity towards NNRTI-resistant mutants, although it is less
potent than 37.
The antiviral activity of 34, 36, and 37 were further tested against wild-type virus and A17
resistant mutant in parallel with drug 4 after it was approved by US FDA and became
available on the market (Table 3). The viral inhibition activity of 37 was slightly better than
that of 4 against HIV-1IIIB (wild-type) in this screening, which double-confirmed our results
in Table 2. Compounds 37 and 4 showed similar activity (EC50: 0.604 and 0.575 μM,
respectively) against A17 (from NIH) with mutations in the viral RT domain that is highly
resistant to NRTIs. These results provide further support that the DAPY pyrimidine ring can
be replaced by a benzene ring to generate new potent compounds as a distinct class of next-
generation NNRTIs. Meanwhile, although compound 34 (R2 = NH2) was not as potent as 4
and 37, it had a higher resistant fold change (RF >73, ratio of EC50 against mutant strain/
EC50 against wild-type strain) against A17 compared with other compounds, suggesting that
the R2 substituent on the central B-ring may play an important role in the anti-HIV-1 activity
against drug-resistant virus.
To confirm RT is the biological target of the newly synthesized diarylaniline analogs,
compounds 34 and 37 were evaluated against viral enzyme RT (from HIV-1DH012 lysate)
and compared with 4. From Figure 3, we can see all three compounds potently inhibited RT
activity. Inhibition of DH012 RT activity by 34 and 37 suggests that HIV-1 RT is a target of
the compounds. However, the anti-RT potency of these two compounds was much weaker
than 4 even though compound 37 was more potent than 4 against HIV-1 replication (Table
3). The discrepancy in potency between anti-HIV-1 replication and anti-RT activity could be
due to the fact that different viral strains were used in the assays. The T cell-adapted virus
HIV-1 IIIB was used in the virus replication assay (Table 3), whereas the primary isolate
DH012 was used for the RT assay. It is also possible that 34 and 37 inhibited HIV-1 RT in a
different manner than 4. In addition to inhibition of the RNA-dependent DNA polymerase
activity of HIV-1 RT, compound 37 might also inhibit DNA-dependent DNA polymerase
activity that could not be optimally detected by the RT assay used in this study.
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Computational studies of three compounds 21, 34 and 37 were carried out to understand
how the substituents on the central B-ring of these diarylaniline analogues might interact
with HIV-1 RT. Due to the high structural similarity with DAPY, the ligand/protein
complexes of the three compounds were created with the help of the experimental crystal
structure of HIV-1 in interaction with DAPY compound (PDB code: 1s6q).11
After energetic optimizations, the ligand positions in the NNRTI binding pocket were
carefully checked. To understand the so-called “induced fit effect,” all complexes were
compared to HIV-RT alone, which was computed by the same protocol. The Root Mean
Square Deviation (RMSD) permits the determination of geometrical variations between the
free and complex protein; all values are compiled in Table 4. From this table, it appears that,
globally, the ligand/protein structure is kept and that only small adaptations are made by the
protein. Comparison of the backbone and side-chain RMSDs shows that the side-chain
residues have moved much more in the optimization process than the peptidic chain,
indicating that the secondary enzyme structure was conserved and only small adaptations of
residues occurred. In comparison, the less biologically active compound 21 induced more
“deformation” (i.e., a higher RMSD) of the protein than either 34 or 37, denoting that the
protein needs a more significant deformation for adaptation to 21, which is energetically
unfavorable for binding.
The Molecular Mechanics/General Born Surface Area (MM/GBSA) technique is one of the
best computational methods to evaluate free energy of binding, generally from molecular
dynamics simulations, for ligands in biological macromolecules.20,21 Recently, it has been
shown on a large number of enzymatic systems (including HIV-1 RT) that the MM/GBSA
method is able to rescore docking results, even with only one minimized structure.22
Therefore, we employed this technique on our three compounds, and the results are
compiled in Table 5. To take into account the protein adaptation to the ligands, the
calculations were made by considering the three species individually (protein, ligand and
complex). The computed free energies of binding paralleled the experimental antiviral
activity data, i.e., the ranking of EC50 values. Furthermore, the energetic decompositions
indicated which contributions are the most important for the binding affinity and which are
not. Comparison of values in Table 5 indicated that the differences of binding free energies
come mainly from the gas phase energy and, more precisely, from the electrostatic
contribution of the ligand to the protein. However, the non-polar solvent effect is almost
identical for the three compounds. This result may reflect the fact that, in the X-ray
structure, the NNRTI binding pocket is deeply inserted into the HIV-1 RT enzyme, and no
water molecules are close to the DAPY ligand. Indeed, non-polar solvent free energy of
binding comes from the entropic desolvation of water around the ligand interacting site.
Based on the above computational studies, the docking of three ligands with HIV-1 RT is
illustrated more clearly in Figure 4. Compounds 21, 34 and 37 differ structurally only in the
identity of the R2 and R4 substituents on the central aromatic ring (21: NO2, NO2; 34: NH2,
NH2; 37: NO2, NH2). Therefore, our analyses focused on these moieties. As shown in
Figure 4, a hydrogen bond between the NH linker and the peptidic carbonyl oxygen of
K101, like that for DAPY compounds, is observed with all three compounds. However, the
neighbouring amino group (R4) present in 34 and 37 provides two more hydrogen bonds
with K101: one is between the peptidic carbonyl oxygen of the protein residue and one NH
vector of the ligand NH2 group and the second one involves the NH atoms of K101 and
targets the nitrogen atom of the ligand NH2 group. The most active compound 37 also has a
nitro group as the R2 substituent on the central ring. This group provides a small
electrostatic interaction with the positively charged K172 (ligand nitrogen – protein nitrogen
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distance of 6.68 Å; see Figure 3, bottom). When the nitro group in 37 was replaced by an
amino group in 34, the corresponding ligand-protein electrostatic interaction decreased (see
Figure 3, middle). Indeed, the distance between the nitrogen atom of the amino moiety of 34
and the K101 nitrogen increased from 6.68 Å to 7.04 Å, indicating that repulsion has
occurred. Moreover, this electrostatic effect was also observed computationally (Table 5)
with electrostatic energy values of -56.5 kcal/mol and -23.8 kcal/mol for 37 and 34,
respectively. In comparison with 34 and 37, the least active compound 21 has two nitro
groups on the central B-ring (see Figure 3, top). Thus, the rightmost (R2) nitro group of 21
has the same electrostatic interaction with K172 found in 37, and the ligand nitrogen –
protein nitrogen distance shortens to 6.56 Å. However, the presence of the leftmost (R4)
nitro group in 21 completely disrupts the hydrogen bond network with K101. The NH atoms
of K101 face the nitrogen atom of the nitro moiety identically as for the amino group, but
the nitrogen of a nitro group is electropositive, while that of an amino group is
electronegative. Thus, for 21, electrostatic repulsion occurs between the R4 nitro group and
the NH of K101, which is also observed in the computational electrostatic energy value of
31.4 kcal/mol (Table 5). Because a hydrogen bond is mainly electrostatic, the two
supplementary H-bonds found with 34 and 37 could explain the experimental EC50
differences, which correlated with the computed free energies of binding. Therefore, these
molecular modeling results also strongly support our hypothesis and demonstrate why the
amino-substituted compounds 29-38 are more potent than nitro-substituted compounds
19-28.
Conclusion
Based on our isosteric replacement strategy, diarylaniline derivatives were discovered as a
distinct class of HIV-1 NNRTI agents. Current results supported our hypothesis that the
NH2 group on the central B-ring ortho to the anilino ring position is crucial for interaction
with K101 on the NNRTI binding site by forming additional H-bonds. In the series of new
compounds, active diarylaniline derivatives are highly potent against both wild-type and
drug resistant HIV-1 strains. Among them, the most promising compound is 37 with low
EC50 values against HIV-1 wild-type (0.003 – 0.005 μM) and several multi-drug-resistant
strains (0.005 - 0.604 μM). Generally speaking, 36 and 37 showed slightly better EC50
values (0.052 and 0.032 μM, respectively) than 4 (EC50 0.058 μM), a newly marketed
HIV-1 NNRTI drug. In addition, they can be synthesized more conveniently than the DAPY
derivatives 4 and 5.23, 24 The present biological and modeling studies further revealed some
important SARs for this series of diarylanilines: 1) the new scaffold can maintain a similar
binding orientation and conformation to those of DAPY derivatives; 2) a para-cyanoaniline
moiety is necessary for anti-HIV activity; 3) an amino group on the central B-ring ortho to
the aniline moiety position is crucial for achieving high potency, likely by forming H-bonds
with K101; 4) an additional nitro group (R2) on the central aromatic ring is helpful for
enhancing affinity of the inhibitor by interaction with K172; and 5) the para-substituent (R3)
on the phenoxy ring is changeable but can greatly affect the anti-HIV activity.
Experimental Section
Chemistry
Melting points were measured with an RY-1 melting apparatus without correction. The
proton nuclear magnetic resonance (1H NMR) spectra were measured on a JNM-ECA-400
(400 MHz) spectrometer using tetramethylsilane (TMS) as the internal standard. The solvent
used was DMSO-d6, unless otherwise indicated. Mass spectra (MS) were measured on an
ABI Perkin-Elmer Sciex API-150 mass spectrometer with electrospray ionization, and the
relative intensity of each ion peak is presented as percent (%). The purities of target
compounds were ≥95% measured by HPLC analyses, which were performed by Agilent
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1100 HPLC system with a UV detector, using a Grace Alltima HP C18 column (100 × 2.1
mm, 3 μm) eluting with a mixture of solvents A and B (condition 1: acetonitrile/water 80:20,
flow rate 0.2 mL/min; condition 2: MeOH/water 80:20, flow rate 0.2 mL/min; UV 254 nm).
The microwave reactions were performed on a microwave reactor from Biotage, Inc. Thin-
layer chromatography (TLC) was performed on silica gel GF254 plates. Silica gel GF254
(200–300 mesh) from Qingdao Haiyang Chemical Company was used for TLC, preparative
TLC, and column chromatography. Medium-pressure column chromatography was
performed using a CombiFlash® CompanionTM purification system. All chemicals were
obtained from Beijing Chemical Works or Sigma-Aldrich, Inc.
General Procedure for the Preparation of N1-Aryl-5-chloro-2-nitroanilines (7-12)
Method A. A para-sustituted aniline (1.1 equiv) was added slowly into a solution of 2,4-
dichloronitrobenzene (1 equiv) in DMF (3 mL) and triethylamine (1.5 mL, excess). The
yellow mixture was stirred at rt for 40 min. The mixture was then poured into water (ca. 30
mL) and stirred for an additional 30 min. The solid product was collected and purified by
recrystallization from EtOH. Method B. To a solution of 2,4-dichloronitrobenzene (1 equiv)
and a substituted aniline (1.1 equiv) in DMF (3 mL), was slowly added potassium tert-
butoxide (2 equiv) at ice-water bath temperature, then stirred at rt for about 1 h until the
reaction was completed as monitored by TLC. The mixture was poured into ice-water, and
pH was adjusted to 6 with 5% aq HCl The solid was collected, washed with water three
times, and purified by recrystallization from EtOH.
5-Chloro-N-(4-methoxyphenyl)-2, 4-dinitroaniline (7)
Method A, yield: 82%, starting with 237 mg (1 mmol) of 1,3-dichloro-4,6-dinitrobenzene
and 136 mg (1.1 mmol) of 4-methoxyaniline to afford 226 mg of 7, yellow solid, mp 150 –
151 °C. 1H NMR (CDCl3) δ ppm 3.88 (3H, s, OCH3), 7.03 (2H, d, J = 8.8 Hz, ArH-3′, 5′),
7.05 (1H, s, ArH-6), 7.21 (2H, d, J = 8.8 Hz, ArH-2′, 6′), 9.09 (1H, s, ArH-3), 9.74 (1H, s,
NH). MS m/z (%) 324 (M+1, 100), 326 (M+3, 30).
5-Chloro-N-(4-methylphenyl)-2,4-dinitroaniline (8)
Method A, yield: 94%, starting with 237 mg (1 mmol) of 1,3-dichloro-4,6-dinitrobenzene
and 118 mg (1.1 mmol) of 4-methylaniline to afford 324 mg of 8, yellow solid, mp 148 –
150 °C. 1H NMR (CDCl3) δ ppm 2.43 (3H, s, CH3), 7.12 (1H, s, ArH-6), 7.17 (2H, d, J =
8.0 Hz, ArH-3′, 5′), 7.32 (2H, d, J = 8.0 Hz, ArH-2′, 6′), 9.09 (1H, s, ArH-3), 9.80 (1H, br.
NH). MS m/z (%): 308 (M+1, 100), 310 (M+3, 31).
5-Chloro-N-(4-chlorophenyl)-2,4-dinitroaniline (9)
Method A, yield: 80%, starting with 237 mg (1 mmol) of 1,3-dichloro-4,6-dinitrobenzene
and 166 mg (1.3 mmol) of 4-chloroaniline at 80 °C for 20 min to afford 263 mg of 9, yellow
solid, mp 136 – 138 °C. 1H NMR (CDCl3) δ ppm 7.11 (1H, s, ArH-6), 7.25 (2H, d, J = 8.8
Hz, ArH-3′, 5′), 7.50 (2H, d, J = 8.8 Hz, ArH-2′, 6′), 9.08 (1H, s, ArH-3), 9.77 (1H, s, NH).
MS (negative charge) m/z (%): 326 (M-1, 100), 328 (M+1, 80).
5-Chloro-N-(4-nitrophenyl)-2,4-dinitroaniline (10)
Method B. yield: 83%, starting with 237 mg (1 mmol) of 1,3-dichloro-4,6-dinitrobenzene
and 166 mg (1.2 mmol) of 4-nitroaniline to afford 280 mg of 10, yellow solid, mp 140 – 141
°C. 1H NMR δ ppm 7.55 (1H, s, ArH-6), 7.60 (2H, d, J = 8.8 Hz, ArH-2′, 6′), 8.29 (2H, d, J
= 8.8 Hz, ArH-3′, 5′), 8.90 (1H, s, ArH-3), 10.19 (1H, s, NH). MS m/z (%): 308 (M+1, 100),
310 (M+3, 30).
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Method B. yield: 89%, starting with 237 mg (1 mmol) of 1,3-dichloro-4,6-dinitrobenzene
and 130 mg (1.1 mmol) of 4-cyanoaniline to afford 284 mg of 11, yellow solid, mp 174 –
176 °C. 1H NMR (CDCl3) δ ppm 7.41 (1H, s, ArH-6), 7.57 (2H, d, J = 8.8 Hz, ArH-2′, 6′),
7.91 ( 2H, d, J = 8.8 Hz, ArH-3′, 5′), 8.90 (1H, s, ArH-3), 10.07 (1H, s, NH). MS m/z (%):
319 (M+1, 100), 321 (M+3, 23).
5-Chloro-N-(4-cyanophenyl)-2-nitroaniline (12)
Method B. yield 71%, starting with 576 mg (3 mmol) of 2,4-dichloro-1-nitrobenzene and
425 mg (3.6 mmol) of 4-cyanoaniline to afford 583 mg of 12, red-yellow solid, mp 123 –
124 °C. 1H NMR δ ppm 7.17 (1H, d, J = 9.0 Hz, ArH-4), 7.40 (2H, d, J = 8.8 Hz, ArH-2′,
6′), 7.45 (1H, s, ArH-6), 7.78 (2H, d, J = 8.8 Hz, ArH-3′, 5′), 8.14 (1H, d, J = 9.0 Hz,
ArH-3), 9.48 (1H, s, NH). MS m/z (%): 272 (M-1, 100), 321 (M+1, 22).
General Preparation of Diphenylether (13-28). Method C (microwave)
A mixture of N-aryl-5-chloro-2-nitroaniline (1 equiv) and 2,6-dimethylphenol (1.2 equiv) in
DMF (3 mL) in the presence of anhydrous potassium carbonate (2 equiv) was irradiated
under microwave with stirring at 190 °C for 15 min. The mixture was poured into ice-water,
pH adjusted to neutral with 5% HCl aq, and the mixture extracted with EtOAc three times.
After removal of organic solvent in vacuo, crude product was purified by PTLC or a silica
column (eluent: petroleum ether/EtOAc). Method D (traditional): A mixture of N-aryl-5-
chloro-2-nitroaniline (11 or b, 1 equiv) and a para-substituted 2,6-dimethylphenol (1.2
equiv) in DMF in the presence of anhydrous potassium carbonate (excess) was heated at 130
°C for 5 h. Work-up was the same as above, and crude product was purified by a silica gel
column.
5-(2″,6″-Dimethylphenoxy)-N-(4-methoxyphenyl)-2,4-dinitroaniline (13)
Method C: yield 75%, starting with 129 mg (0.4 mmol) of 7 and 59 mg (0.48 mmol) of 2,6-
dimethylphenol to afford 123 mg of 13, yellow solid, mp 169-170 °C. 1H NMR (CDCl3) δ
ppm 2.06 (6H, s, 2×CH3), 3.78 (3H, s, OCH3), 5.91 (1H, s, ArH-6), 6.75 (2H, d, J = 8.8 Hz,
ArH-2′, 6′), 6.89 (2H, d, J = 8.8 Hz, ArH-3′, 5′), 7.11 (1H, t, J = 6.8 Hz, ArH-4′′), 7.69 (2H,
d, J = 6.8 Hz, ArH-3″, 5″), 8.96 (1H, s, ArH-3), 9.70 (1H, s, NH). MS m/z (%):410 (M+1,
100); HPLC Purity: 99.4%.
N1-(4′-Methoxyphenyl)-5-(2″,4″,6″-trimethylphenoxy)-2,4-dinitroaniline (14)
Method C: yield 33%, starting with 162 mg (0.5 mmol) of 7 and 82 mg (0.6 mmol) of 2,4,6-
trimethylphenol to afford 70 mg of 14, red solid, mp 155-158 °C. 1H NMR (CDCl3) δ ppm
1.98 (6H, s, 2×CH3), 2.16 (3H, s, CH3), 3.73 (3H, s, OCH3), 5.82 (1H, s, ArH-6), 6.69 (2H,
s, ArH), 6.72 (2H, d, J = 8.8 Hz, ArH-2′, 6′), 6.84 (2H, d, J = 8.8 Hz, ArH-3′, 5′), 9.11 (1H,
s, ArH-3), 9.60 (1H, s, NH). MS m/z (%):424 (M+1, 100); HPLC Purity: 98.3%.
5-(4″-Bromo-2″,6″-dimethylphenoxy)-N-(4′-methoxyphenyl)-2,4-dinitroaniline (15)
Method C: yield 53%, starting with 647 mg (2 mmol) of 7 and 422 mg (2.1 mmol) of 4-
bromo-2,6-dimethylphenol to afford 517 mg of 15, yellow solid, mp 221 – 223 °C. 1H NMR
(CDCl3) δ ppm 2.07 (6H, s, 2×CH3), 3.78 (3H, s, OCH3), 5.91 (1H, s, ArH-6), 6.75 (2H, d, J
= 9.0 Hz, ArH-2′, 6′), 6.89 (2H, d, J = 9.0 Hz, ArH-3′, 5′), 7.34 (2H, s, ArH-3″, 5″), 9.17
(1H, s, ArH-3), 9.68 (1H, s, NH). MS m/z (%): 488 (M+1, 100), 490 (M+3, 98); HPLC
Purity: 95.8%.
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Method C: yield 52%, starting with 154 mg (0.5 mmol) of 8 and 121 mg (0.6 mmol) of 4-
bromo-2, 6-dimethylphenol to afford 123 mg of 16, yellow solid, mp 200 – 202 °C. 1H
NMR (CDCl3) δ ppm 2.08 (6H, s, 2×CH3), 2.36 (3H, s, CH3), 5.89 (1H, s, ArH-6), 6.86
(2H, d, J = 8.8 Hz, ArH-3′, 5′), 7.10 (2H, d, J = 8.8 Hz, ArH-2′, 6′), 7.16 (2H, s, ArH-3″, 5″),
9.17 (1H, s, ArH-3), 9.71 (1H, s, NH). MS m/z (%):472 (M+1, 100), 474 (M+3, 92); HPLC
Purity: 97.5%.
5-(4″-Bromo-2″,6″-dimethylphenoxy)-N-(4′-chlorophenyl)-2,4-dinitroaniline (17)
Method C: yield: 64%, starting with 328 mg (1.0 mmol) of 9 and 201 mg (1.0 mmol) of 4-
bromo-2,6-dimethylphenol to afford 315 mg of 17, yellow solid, mp 206 – 208 °C. 1H NMR
δ ppm 2.01 (6H, s, 2×CH3), 5.70 (1H, s, ArH-6), 7.15 (2H, d, J = 8.8 Hz, ArH-3′, 5′), 7.35
(2H, d, J = 8.8 Hz, ArH-2′, 6′), 7.37 (2H, s, ArH-3″, 5″), 8.96 (1H, s, ArH-3), 10.01 (1H, s,
NH). MS m/z (%): 492 (M+1, 70), 494 (M+3, 100); HPLC Purity: 96.3%. 5-(4″-Bromo-2″,
6″-dimethylphenoxy)-N-(4′-nitrophenyl)-2,4-dinitroaniline (18)
Method C: yield 78%, starting with 154 mg (0.44 mmol) of 10 and 107 mg (0.53 mmol) of
4-bromo-2, 6-dimethylphenol to afford 173 mg of 18, yellow solid, mp 190 – 191 °C. 1H
NMR δ ppm 2.05 (6H, s, 2×CH3), 6.06 (1H, s, ArH-6), 7.31 (2H, d, J = 8.8 Hz, ArH-2′, 6′),
7.41 (2H, s, ArH-3″, 5″), 8.13 (2H, d, J = 8.8 Hz, ArH-3′, 5′), 8.96 (1H, s, ArH-3), 10.13
(1H, s, NH). MS m/z (%): 503 (M+1, 100), 505 (M+3, 98); HPLC Purity: 97.7%.
5-(4″-Bromo-2″,6″-dimethylphenoxy)-N-(4′-cyanophenyl)-2,4-dinitrsoaniline (19)
Method D: yield 85%, starting with 3.18 g (10 mmol) of 11 and 2.4 g (12 mmol) of 2,6-
dimethyl-4-bromophenol in the presence of K2CO3 (excess, 3.0 g, 21.7 mmol) to afford 4.3
g of 19, yellow solid, mp 276 – 278 °C. 1H NMR δ ppm 2.05 (6H, s, 2×CH3 ), 5.93 (1H, s,
ArH-6), 7.28 (2H, d, J = 8.8 Hz, ArH-2′, 6′), 7.42 (2H, s, ArH-3″, 5″), 7.73 (2H, d, J = 8.8
Hz, ArH-3′, 5′), 8.96 (1H, s, ArH-3), 10.07 (1H, s, NH). MS (negative charge) m/z (%): 481
(M-1, 100), 483 (M+1, 99); HPLC Purity: 98.5%.
N-(4′-Cyanophenyl)-5-(2″,6″-dimethylphenoxy)-2,4-dinitroaniline (20)
Method C: yield: 81%, starting with 319 mg (1.0 mmol) of 11 and 146.4 mg (1.2 mmol) of
2,6-dimethylphenol to afford 327 mg of 20, orange solid, mp 229 } 230 °C. 1H NMR δ ppm
2.06 (6H, s, 2×CH3), 6.01 (1H, s, ArH-6), 7.09 (2H, d, J = 8.8 Hz, ArH-2′, 6′), 7.11 (1H, t, J
= 6.8 Hz, ArH-4″), 7.28 (2H, d, J = 8.8 Hz, ArH-3′, 5′), 7.69 (2H, d, J = 6.8 Hz, ArH-3″, 5″),
8.96 (1H, s, ArH-3), 10.07 (1H, s, NH). MS m/z (%):405 (M+1, 100); HPLC Purity: 99.9%.
5-(4″-Cyano-2″,6″-dimethylphenoxy)-N-(4′-cyanophenyl)-2,4-dinitroaniline (21)
Method D: yield 94%, starting with 1.27 g (4.0 mmol) of 11 and 705 mg (4.8 mmol) of 2,6-
dimethyl-4-cyanophenol in DMF (4 mL) in the presence of anhydrous potassium carbonate
(966 mg, 7 mmol) to afford 1.61g of 21, orange solid, mp >300°C. 1H NMR δ ppm 2.08
(6H, s, 2×CH3), 5.90 (1H, s, ArH-6), 7.29 (2H, d, J = 8.8 Hz, ArH-2′, 6′), 7.73 (2H, s,
ArH-3″, 5″), 7.74 (2H, d, J = 8.8 Hz, ArH-3′, 5′), 8.97 (1H, s, ArH-3), 10.07 (1H, s, NH).
MS m/z (%): 430 (M+1, 100); HPLC Purity: 98.1%.
N-(4′-Cyanophenyl)-2,4-dinitro-5-(2″,4″,6″-trimethylphenoxy)aniline (22)
Method C: yield 70%, starting with 637 mg (2 mmol) of 11 and 286 mg (2.1 mmol) of 2,4,6-
trimethylphenol to afford 580 mg of 22, yellow solid, mp 223 – 225 °C. 1H NMR δ ppm
2.00 (6H, s, 2×CH3), 2.22 (3H, s, CH3), 5.92 (1H, s, ArH-6), 6.95 (2H, s, ArH-3″, 5″), 7.27
(2H, d, J = 8.8 Hz, ArH-2′, 6′), 7.72 (2H, d, J = 8.8 Hz, ArH-3′, 5′), 8.95 (1H, s, ArH-3),
10.04 (1H, s, NH). MS m/z (%):419 (M+1, 100); HPLC Purity: 98.3%.
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Method C: yield 74%, starting with 160 mg (0.5 mmol) of 11 and 113 mg (0.6 mmol) 4-
hydroxy-3,5-dimethylbenzaldehyde to afford 144 mg of 23, yellow solid, mp 260 – 263
°C. 1H NMR (CDCl3) δ ppm 2.23 (6H, s, 2×CH3), 6.24 (1H, s, ArH-6), 7.10 (2H, d, J = 8.8
Hz, ArH-2′, 6′), 7.54 (2H, d, J = 8.8 Hz, ArH-3′, 5′), 7.67 (2H, s, ArH-3″, 5″), 9.20 (1H, s,
ArH-3), 9.97 (2H, s, NH & CHO), MS m/z (%)433 (M+1, 100); HPLC Purity: 98.7%.
5-(4″-Bromo-2″,6″-dimethylphenoxy)-N-(4′-cyanophenyl)-2-nitroaniline (24)
Method C: yield: 93%, starting with 12 (100 mg, 0.36 mmol) and potassium 4-bromo-2,6-
dimethylphenoxide (105 mg, 0.44 mmol) in DMF (2 mL) were irradiated under microwave
with stirring at 192 °C for 10 min to get 147 mg of 24, light yellow solid, mp 143 °C. 1H
NMR (CDCl3) δ ppm 2.03 (6H, s, 2×CH3), 6.19 (1H, dd, J = 9.2 & 2.4 Hz, ArH-6), 6.74
(1H, d, J = 2.4 Hz, ArH-4), 7.21 (2H, d, J = 8.8 Hz, ArH-2′, 6′, 7.30 (2H, s, ArH-3″, 5″),
7.57 (2H, d, J = 8.8 Hz, ArH-3′, 5′), 8.13 (1H, d, J = 9.2 Hz, ArH-3), 9.69 (1H, s, NH). MS
m/z (%): 438 (M+1. 100), 440 (M+3, 98); HPLC Purity: 95.7%.
N-(4′-Cyanophenyl)-5-(2″,6″-dimethylphenoxy)-2-nitroaniline (25)
Method C: yield: 31%, starting with 12 (50 mg, 0.18 mmol) and 2,6-dimethylphenol (31 mg,
0. 25 mmol) in the presence of potassium carbonate (58 mg, 0.42 mmol) in DMSO (2 mL)
to afford 20 mg of 25, yellow solid, mp 158-60 °C. 1H NMR (CDCl3, 400 MHz) d 2.12 (6H,
s, 2×CH3), 6.35 (1H, q, J1 = 9.2 Hz, J2 = 2.4 Hz, ArH-4), 6.73 (1H, d, J = 2.4 Hz, ArH-6),
7.10 (3H, m, ArH-3″, 4″, 5″), 7.24 (2H, d, J = 8.4 Hz, ArH-2′, 6′), 7.59 (2H, d, J = 8.4 Hz,
ArH-3′, 5′), 8.21 (1H, d, J = 9.2 Hz, ArH-3), 9.76 (1H, s, NH). MS m/z (%): 360 (M+, 100);
HPLC Purity: 96.6%.
5-(4″-Cyano-2″,6″-dimethylphenoxy)-N-(4′-cyanophenyl)-2-nitroaniline (26)
Method D: yield 79%, starting with 821 mg (3 mmol) of 12 and 530 mg (3.6 mmol) of 2,6-
dimethyl-4-cyanophenol in the presence of K2CO3 (excess, 1.45 g, 10.5 mmol) to afford
0.92 g of 26, yellow solid, mp186 – 188 °C. 1H NMR (CDCl3) δ ppm 2.16 (6H, s, 2×CH3),
6.15 (1H, dd, J = 9.2 & 2.4 Hz, ArH-4), 6.87 (1H, d, J = 2.4 Hz, ArH-6), 7.31 (2H, d, J = 8.8
Hz, ArH-2′, 6′), 7.45 (2H, s, ArH-3″, 5″), 7.66 (2H, d, J = 8.8 Hz, ArH-3′, 5′), 8.21 (1H, d, J
= 9.2 Hz, ArH-3), 9.75 (1H, s, NH). MS m/z (%):385 (M+1, 100); HPLC Purity: 99.0%.
N-(4′-Cyanophenyl)-5-(2″,4″,6″-trimethylphenoxy)-2-nitroaniline (27)
Method D: yield 74%, starting with 274 mg (1 mmol) of 12 and 241 mg (1.2 mmol) of
2,4,6-trimethylphenol in the presence of excess K2CO3 to afford 225 mg of 27, yellow solid,
mp 168 – 170 °C; 1H NMR (CDCl3) δ ppm 2.00 (6H, s, 2×CH3), 2.23 (3H, s, CH3), 6.25
(1H, d, J = 9.2 Hz, ArH-4), 6.69 (1H, s, ArH-6), 6.84 (2H, s, ArH-3″, 5″), 7.18 (2H, d, J =
8.8 Hz, ArH-2′, 6′), 7.53 (2H, d, J = 8.8 Hz, ArH-3′, 5′), 8.12 (1H, d, J = 9.2 Hz, ArH-3),
9.67 (1H, s, NH); MS m/z (%) 474 (M+1, 100); HPLC Purity: 95.9%.
N-(4′-Cyanophenyl)-5-(2″,6″-dimethyl-4″-formylphenoxy)-2-nitroaniline (28)
Method C: yield 70%, starting with 137 mg (0.5 mmol) of 12 and 90 mg (0.6 mmol) of 4-
hydroxy-3,5- dimethylbenzaldehyde to afford 135 mg of 28, yellow solid, mp 152 – 155
°C. 1H NMR (CDCl3) δ ppm 2.21 (6H, s, 2×CH3), 6.23 (1H, dd, J = 8.8 & 2.4 Hz, ArH-4),
6.84 (1H, d, J = 2.4 Hz, ArH-6), 7.30 (2H, d, J = 8.8 Hz, ArH-2′, 6′), 7.64 (2H, d, J = 8.8 Hz,
ArH-3′, 5′), 7.67 (2H, s, ArH), 8.22 (1H, d, J = 8.8 Hz, ArH-3), 9.76 (1H, br. s, NH), 9.97
(1H, s, CHO). MS m/z (%): 338 (M+1, 100); HPLC Purity: 98.6%.
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General Preparation of 1,5-Diarylbenzene-1,2-diamines or 1,2,4-Triamines (29-38)
To a solution of a diaryl-nitrobenzene (24, 26-27 or 19-22, 1 equiv) in 15 mL of isopropanol
was added FeCl3·6H2O (1 equiv), activated carbon (2 equiv), and N2H4·H2O (10 equiv),
successively. The mixture was refluxed for 20-30 min. After removal of carbon and solvent,
the residue was purified by a silica gel column (eluent: CHCl3/MeOH 40:1) to obtain
corresponding diarylbenzene-1,2-diamine or -1,2,4-triamines respectively.
5-(4″-Bromo-2″,6″-dimethylphenoxy)-N1-(4′-cyanophenyl)benzene-1,2-diamine (29)
Yield 83%, starting with 150 mg (0.34 mmol) of 24 to afford 115 mg of 29, brown solid, mp
154 – 155 °C. 1H NMR d ppm 2.07 (6H, s, 2×CH3), 4.55 (2H, s, ArNH2), 6.34 (1H, s,
ArH-6), 6.47 (1H, d, J = 8.8 Hz, ArH-4), 6.65 (2H, d, J = 8.8 Hz, ArH-2′, 6′), 6.73 (1H, d, J
= 8.8 Hz, ArH-3), 7.34 (2H, s, ArH-3″, 5″), 7.49 (2H, d, J = 8.8 Hz, ArH-3′, 5′), 8.08 (1H, s,
NH); MS m/z (%) 408 (M+1, 100), 410 (M+3, 98); HPLC Purity: 96.8%.
5-(4″-Cyano-2″,6″-dimethylphenoxy)-N1-(4′-cyanophenyl)benzene-1,2-diamine (30)
Yield 83%, starting with 130 mg (0.34 mmol) of 26 to afford 100 mg of 30, brown solid, mp
154 – 156 °C. 1H NMR (CDCl3) δ ppm 2.18 (6H, s, 2×CH3), 3.0-4.0 (2H, NH2), 5.67 (1H,
s, NH), 6.47 (1H, q, J = 8.8 & 2.8 Hz, ArH-4), 6.58 (1H, d, J = 2.8 Hz, ArH-6), 6.70 (2H, d,
J = 8.8 Hz, ArH-2′, 6′), 6.74 (1H, d, J = 8.8 Hz, ArH-3), 7.40 (2H, s, ArH-3″, 5″), 7.47 (2H,
d, J = 8.8 Hz, ArH-3′, 5′). MS m/z (%): 355 (M+1, 100); HPLC Purity: 99.2%.
N1-(4′-Cyanophenyl)-5-(2″,4″,6″-trimethylphenoxy)benzene-1,2-diamine (31)
Yield 84%, starting with 150 mg (0.4 mmol) of 27 to afford 116 mg of 31, mp152 – 154
°C. 1H NMR δ ppm 2.02 (6H, s, 2×CH3), 2.22 (3H, s, CH3), 4.48 (2H, s, NH2), 6.29 (1H, d,
J = 2.8 Hz, ArH-6), 6.48 (1H, dd, J = 8.4 & 2.8 Hz, ArH-4), 6.64 (1H, d, J = 8.4 Hz, ArH-3),
6.72 (2H, d, J = 8.8 Hz, ArH-2′, 6′), 7.48 (2H, d, J = 8.8 Hz, ArH-3′, 5′), 8.07 (1H, s, NH).
MS m/z (%): 344 (M+1, 100); HPLC Purity: 99.8%.
5-(4″-Bromo-2″,6″-dimethylphenoxy)-N1-(4′-cyanophenyl)benzene-1,2,4-triamine (32)
Yield 95%, starting with 150 mg (0.31 mmol) of 19 to afford 125 mg of 32, brown solid, mp
181 – 183 °C. 1H NMR δ ppm 2.08 (6H, s, 2×CH3), 4.28 (2H, s, NH2), 4.91 (2H, s, NH2),
5.70 (1H, s, ArH-3), 6.22 (1H, s, ArH-6), 6.43 (2H, d, J = 8.8 Hz, ArH-2′, 6′), 7.30 (2H, s,
ArH-3″, 5″), 7.38 (2H, d, J = 8.8 Hz, ArH-3′, 5′), 7.71 (1H, s, NH). MS m/z (%): 423 (M+1,
100), 425 (M+3, 98); HPLC Purity: 96.1%.
N1-(4′-Cyanophenyl)-5-(2″,6″-dimethylphenoxy)benzene-1,2,4-triamine (33)
Yield 30%, starting with 152 mg (0.31 mmol) of 20 to afford 39 mg of 33, brown solid, mp
156-8 °C. 1H NMR δ ppm 2.08 (6H, s, 2×CH3), 4.22 (2H, s, NH2-4), 4.84 (2H,s, NH2-2),
5.70 (1H, s, ArH-3), 6.23 (1H, s, ArH-6), 6.43 (2H, d, J = 8.8 Hz, ArH-2′, 6′), 6.99 (2H, d, J
= 6.8 Hz, ArH-3″, 5″), 7.07 (1H, t, J = 6.8 Hz, ArH-4”), 7.36 (2H, d, J = 8.8 Hz, ArH-3′, 5′),
7.67 (1H, s, NH). MS m/z (%): 345 (M+, 100); HPLC Purity: 99.6%.
5-(4″-Cyano-2″,6″-dimethylphenoxy)-N1-(4′-cyanophenyl)benzene-1,2,4-triamine (34)
Yield 86%, starting with 300 mg (0.7 mmol) of 21 to afford 223 mg of 34, brown solid, mp
144 °C; 1H NMR δ ppm 2.08 (6H, s, 2×CH3), 4.33 (2H, s, NH2), 4.97 (2H, s, NH2), 5.71
(1H, s, ArH-3), 6.23 (1H, s, ArH-6), 6.43 (2H, d, J = 8.8 Hz, ArH-2′, 6′), 7.38 (2H, d, J = 8.8
Hz, ArH-3′, 5′), 7.61 (2H, s, ArH-3″, 5″), 7.71 (1H, s, NH); MS m/z (%) 370 (M+1, 100);
HPLC Purity: 100.0%.
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Yield 85%, starting with 150 mg (0.36 mmol) of 22 to afford 110 mg of 35, light brown
solid, mp 152 – 154 °C. 1H NMR (CDCl3) δ ppm 2.08 (6H, s, 2×CH3), 2.26 (3H, s, CH3),
3.50 (2H, s, NH2), 4.0 (2H, s, NH2), 5.33 (1H, s, ArH-6), 5.97 (1H, s, ArH-3), 6.29 (1H, s,
NH), 6.47 (2H, d, J = 8.8 Hz, ArH-2′, 6′), 6.86 (2H, s, ArH-3″, 5″), 7.36 (2H, d, J = 8.8 Hz,
ArH-3′, 5′). MS m/z (%): 359 (M+1, 100); HPLC Purity: 100.0%.
5-(4″-Bromo-2″,6″-dimethylphenoxy)-N1-(4′-cyanophenyl)-4-nitrobenzene-1,2-diamine (36)
Pd-C (10%, 30 mg) was added to a solution of 19 (338 mg, 0.7 mmol) in acetonitrile (6 mL)
and triethylamine (6 mL). The mixture was cooled to -15 °C and then formic acid (95%, 1
mL, excess) in acetonitrile (4 mL) was slowly added at the low temperature. The mixture
was then heated to reflux for 1 h, following which the Pd-C and solvent were removed. The
residue was purified by PTLC (petroleum ether/EtOAc 4:1) to obtain 269 mg of 36, yield
85%, deep red solid, mp 218 – 220 °C. 1H NMR δ ppm 2.07 (6H, s, 2×CH3), 5.13 (2H, s,
NH2), 6.16 (1H, s, ArH-6), 6.82 (2H, d, J = 8.4 Hz, ArH-2′,6′), 7.40 (2H, s, ArH-3″, 5″),
7.55 (2H, d, J = 8.4 Hz, ArH-3′,5′), 7.95 (1H, s, ArH-3), 8.45 (1H, s, NH). MS m/z (%) 453
(M+1, 95), 455 (M+3, 100); HPLC Purity: 97.0%.
5-(4″-Cyano-2″,6″-dimethylphenoxy)-N1-(4′-cyanophenyl)-4-nitrobenzene-1,2-diamine (37)
The preparation was the same as that of 36. Yield 86%, starting with 150 mg (0.35 mmol) of
21 to afford 237 mg of 37, red solid, mp 224 – 226 °C. 1H NMR δ ppm 2.07 (6H, s, 2×CH3),
5.17 (2H, s, NH2), 6.15 (1H, s, ArH-6), 6.81 (2H, d, J = 8.8 Hz, ArH-2′, 6′), 7.55 (2H, d, J =
8.8 Hz, ArH-3′, 5′), 7.71 (2H, s, ArH), 8.06 (1H, s, ArH-3), 8.45 (1H, s, NH). MS m/z (%):
400 (M+1, 100); HPLC Purity: 96.8%.
N1-(4′-Cyanophenyl)-5-(2″,4″,6″-trimethylphenoxy)-4-nitrobenzene-1,2-diamine (38)
The preparation was the same as that of 36. Yield 79%, starting with 300 mg (0.72 mmol) of
22 to afford 220 mg of 38, red solid, mp 110 – 112 °C. 1H NMR (CDCl3) δ ppm 2.07 (6H, s,
2×CH3), 2.28 (3H, s, CH3), 6.36 (1H, s, ArH-6), 6.76 2H, d, J = 8.8 Hz, ArH-2′, 6′), 6.89
(2H, s, ArH-3″, 5″), 7.45 (2H, d, J = 8.8 Hz, ArH-3′, 5′), 7.62 (1H, s, ArH-3). MS m/z (%):
389 (M+1, 100); HPLC Purity: 98.3%.
6-(4-Cyano-2,6-dimethylphenoxy)-1-(4-cyanophenyl)-5-nitro-1H-benzoimidazole (39)
Triethyl orthoformate (1 mL, excess) and HCl in diethyl ether (1N, 1 mL) were added
successively to a solution of 37 (50 mg, 0.125 mmol) in DMF (3 mL) under N2. The mixture
was stirred at rt for 3 h, poured into water with pH adjusted to 6-7, and left to stand
overnight. The resulting yellow solid was collected and washed with water. The crude
product was purified by a silica gel column (eluent: CH2Cl2/EtOAc 10:1) to afford 42 mg of
39, yield 88%, light yellow solid, mp 250 – 252 °C. 1H NMR (CDCl3) δ ppm 2.21 (6H, s,
2×CH3), 6.43 (1H, s, ArH-7), 7.43 (2H, d, J = 8.8 Hz, ArH-3′, 5′), 7.46 (2H, s, ArH-3″, 5″),
7.86 (2H, d, J = 8.8 Hz, ArH-2′, 6′), 8.16 (1H, s, ArH-2), 8.54 (1H, s, ArH-4). MS m/z (%):
410 (M+1, 100); HPLC Purity: 96.0%.
(4″-Cyano-2″,6″-dimethylphenoxy)-N1-(4′-cyanophenyl)-4-nitrobenzene-1,2-diamine
hydrochloride (40)
To a solution of 36 (100 mg) in acetone (10 mL) was slowly added HCl diethyl ether
solution (18%, 3 mL), and a light yellow solid appeared. The solid was filtered out and
recrystallized from anhydrous MeOH to afford 52 mg of 40, yield 48%, yellow solid, mp
170 – 171 °C; 1H NMR δ ppm 2.07 (6H, s, 2×CH3), 6.17 (1H, s, ArH-6), 6.83 (2H, d, J =
8.8 Hz, ArH-2′, 6′), 7.40 (2H, s, ArH-3″, 5″), 7. 54 (1H, s, ArH-3), 7.56 (2H, d, J = 8.8 Hz,
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ArH-3′, 5′), 8.50 (1H, s, NH); MS m/z (%) 453 (M+1, 100), 455 (M+3, 100); HPLC Purity:
97.6%.
HIV Growth Inhibition Assay in H9 Lymphocytes from Panacos, Inc
The evaluation of HIV-1 inhibition was carried out as follows according to established
protocols. The human T-cell line, H9, was maintained in continuous culture with complete
medium (RPMI 1640 with 10% fetal calf serum supplemented with L-glutamine at 5% CO2
and 37 °C. Test samples were first dissolved in dimethyl sulfoxide at a concentration of 10
mg/mL to generate master stocks with dilutions made into tissue culture media to generate
working stocks. The following drug concentrations were routinely used for screening: 100,
20, 4 and 0.8 μg/mL. For agents found to be active, additional dilutions were prepared for
subsequent testing so that an accurate EC50 value could be determined. Test samples were
prepared and to each sample well was added 90 μL of media containing H9 cells at 3 × 105
cells/mL and 45 μL of virus inoculum (HIV-1 IIIB isolate) containing 125 TCID50. Control
wells containing virus and cells only (no drug) and cells only (no virus or drug) were also
prepared. A second set of samples were prepared identical to the first and were added to
cells under identical conditions without virus (mock infection) for toxicity determinations
(IC50 defined below). In addition, AZT was also assayed during each experiment as a
positive drug control. On days 1 and 4 post-infection (PI), spent media was removed from
each well and replaced with fresh media. On day 6 PI, the assay was terminated and culture
supernatants were harvested for analysis of virus replication by p24 antigen capture.
Compound toxicity was determined by XTT using the mock-infected samples.
Assay for Measuring the Inhibitory Activity of Compounds on HIV-1 IIIB Replication in
MT-2 Cells
The inhibitory activity of compounds on HIV-1 IIIB replication was determined as
previously described. In brief, 1 × 104 MT-2 cells were infected with an HIV-1 strain (100
TCID50) in 200 μL RPMI 1640 medium containing 10% FBS in the presence or absence of
a test compound at graded concentrations overnight. Then, the culture supernatants were
removed and fresh media containing no test compounds were added. On the fourth day post-
infection, 100 μL of culture supernatants were collected from each well, mixed with equal
volumes of 5% Triton X-100 and assayed for p24 antigen, which was quantitated by ELISA.
Briefly, wells of polystyrene plates (Immulon 1B, Dynex Technology, Chantilly, VA) were
coated with HIV immunoglobulin (HIVIG) in 0.085 M carbonate-bicarbonate buffer (pH
9.6) at 4 °C overnight, followed by washes with washing buffer (0.01M PBS containing
0.05% Tween-20) and blocking with PBS containing 1% dry fat-free milk (Bio-Rad, Inc.,
Hercules, CA). Virus lysates were added to the wells and incubated at 37 °C for 1 h. After
extensive washes, anti-p24 mAb (183-12H-5C), biotin-labeled anti-mouse IgG1 (Santa Cruz
Biotech., Santa Cruz, CA), streptavidin-labeled horseradish peroxidase (Zymed, S. San
Francisco, CA), and the substrate 3,3′,5,5′-tetramethylbenzidine (Sigma Chemical Co., St.
Louis, MO) were added sequentially. Reactions were terminated by addition of 1N H2SO4.
Absorbance at 450 nm was recorded in an ELISA reader (Ultra 386, TECAN, Research
Triangle Park, NC). Recombinant protein p24 purchased from US Biological (Swampscott,
MA) was included for establishing standard dose response curves. Each sample was tested
in triplicate. The percentage of inhibition of p24 production was calculated as previously
described.25 The effective concentrations for 50% inhibition (EC50) were calculated using a
computer program, designated CalcuSyn,26 kindly provided by Dr. T. C. Chou (Sloan-
Kettering Cancer Center, New York, New York).
HIV-1 Infectivity Assay with Mutant Viral Strains in MT-2 Cell Line
A diluted drug resistant HIV-1 stock, mutated viral strain (8605MR or 6005MR from
Panacos, Inc), at a multiplicity of infection (MOI) of 0.001 TCID50/cell was used to infect
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MT-2 cells. Twenty μL of the virus and 20 μL of compounds at various concentrations in
RPMI 1640 containing 10% fetal bovine serum were added to 20 μL of MT4 cells at 6 × 105
cells/mL in a 96-well microtiter plate. The cell/virus /compound mixture was then incubated
at 37°C in a humidified CO2 incubator. Fresh medium (180 μL) containing an appropriate
concentration of the compound was added to each well of the cultures on day 2. On day 4
post-infection, supernatant samples were harvested and assayed for P24 using an ELISA kit
from ZeptoMetrix Corporation, Buffalo, New York.
Assessment of In Vitro Cytotoxicity in MT-2 Cells
The in vitro cytotoxicity of compounds on MT-2 cells was measured by XTT assay.27
Briefly, 100 μL of the test compound at graded concentrations were added to equal volumes
of cells (5 × 105/mL) in wells of a 96-well plate. After incubation at 37 °C for 4 days, 50 μL
of XTT solution (1 mg/mL) containing 0.02 μM of phenazine methosulphate (PMS) was
added. After 4 h, the absorbance at 450 nm was measured with an ELISA reader. The CC50
(concentration for 50% cytotoxicity) values were calculated using the CalcuSyn computer
program as described above.
Assay for RT Enzymatic Inhibition
The RT activity of HIV-1DH012 (a primary isolate viral strain) was determined in the
presence of various concentrations of the tested compounds using a Roche colorimetric
HIV-1 RT assay kit following the protocol provided by the manufacturer.
Computational Study
Three-dimensional constructions of compounds 21, 34 and 37 were achieved by using the
Sybyl version 7.2 software with the tripos force-field and Gasteiger-Hückel atomic partial
charges.28 In order to get the correct orientation of the three compounds inside the HIV-1
RT enzyme, the constructions were made by modifying the experimental coordinates of the
DAPY compound in the HIV-1 RT enzyme (PDB code 1s6q). Then, the compounds were
optimized with 20 simplex iterations followed by 1000 steps of Powell algorithm.
Energy minimizations were obtained with the Amber 9 software.29 Ligand parameters were
created according to the antechamber procedure and the partial charges were evaluated
following the AM1 bond charge correction (AM1-BCC) method.30-32 The general amber
force field33 (gaff) was set for the ligand, whereas the ff03 force field34 was used for the
protein. Minimizations were done with 1000 steps of steepest descent followed by 4000
steps of conjugate gradient. Solvent effects were taken into account through general born
model implicit solvent model.35-38 The Molecular Mechanics/General Born Surface Area
(MM/GBSA) method39-41 permitted the evaluation of the ligand/protein interaction free
energies, and calculation details may be found elsewhere.42 Finally, VMD software43 was
employed to visualize and analyze the 3D structures resulting from AMBER calculations.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Abbreviations
CC50 concentration for 50% cytotoxicity
DAPY diarylpyrimidine
EC50 effective concentration for 50% inhibition
HAART highly active antiretroviral therapy
HIV human immunodeficiency virus
MM/GBSA molecular mechanism/general born surface area
NNRTI non-nucleoside reverse transcriptase inhibitor
NRTI nucleoside reverse transcriptase inhibitor
PDB protein data base
PI protease inhibitor
RF resistant fold
RMSD root mean square deviation
RT reverse transcriptase
RTI reverse transcriptase inhibitor
SAR structure-activity relationship
SI selective index (ratio of CC50/EC50)
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HIV-1 NNRTI agents (1-6).
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Design of Target Compounds.
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RT inhibition activity of diarylanaline analogs 34 and 37*
* Data provided by Dr. Chin-Ho Chen, Duke University Medical Center, US. Results are
average of three independent assays. The RT used in the assays is from HIV-1DH012 lysate.
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21 (top), 34 (middle) and 37 (bottom) in interaction with HIV-1 RT.
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Synthesis of target compounds 13-28. “c or d” indicated two different reaction conditions,
the former is under microwave irradiation and the later is a traditional heating method. a)
Et3N/DMF, r.t. 40 min; b) t-BuOK/DMF, r.t. 1 h; c) K2CO3/DMF or DMSO, 190 °C, MW,
10-15 min; d) K2CO3/DMF, 130 °C, 5h.
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a) FeCl3·6H2O/C, N2H4·H2O, (CH3)2CHOH, reflux, 20-30 min; b) Et3N/HCOOH, Pd/C,
CH3CN, reflux, 1 h; c) triethyl orthoformate, HCl (1N in diethyl ether), r.t. 3 h; d)
CH3COCH3, HCl (18% in diethyl ether).
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Table 3
Data against HIV-1IIIB and A17 in the MT-2 cell line*
Compound
EC50 (μM) in MT-2 cell line
RF
IIIB (wild-type) A17 (Y181C/K103N) a
34 0.211 ± 0.053 15.469 ± 9.035 73.3
36 0.052 ± 0.005 1.055 ± 0.088 20.3
37 0.032 ± 0.005 0.604 ± 0.179 18.9
4 0.058 ± 0.001 0.575 ± 0.093 9.9
*
Data provided by Dr. Shibo Jiang, New York Blood Center, US. Results are average of three independent assays.
a
The multi-NRTI-resistant strain A17 from NIH with mutations at amino acids 103 (K → N) and 181 (Y → C) in the viral RT domain is highly
resistant to NRTIs21.
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Table 4




21 0.666 0.501 0.738
34 0.654 0.493 0.725
37 0.635 0.480 0.703
*
Values are divided into Global (all protein atoms), Backbone (peptidic bonds) and Side-chain (only side-chain atoms).
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Table 5
MM/GBSA Energetic values of the three ligand/HIV-1 RT complexes*.
Ligand 21 34 37
Energy kcal/mol
ΔEelec 31.4 −23.8 −56.5
ΔEvdw −53.8 −61.3 −55.5
ΔEint 14.4 7.2 −8.3
ΔEgas −8.0 −77.9 −120.3
ΔGsolvent_np −6.2 −6.9 −6.4
ΔGsolvent_p 1.5 35.3 54.6
ΔGsolvent −4.7 28.4 48.2
ΔG −12.7 −49.6 −72.1
*
Eelec, Evdw and Eint signify: electrostatic, van der Waals and internal (bonds + angles + dihedrals) energies in gas phase (in vacuo), respectively.
Egas is the sum of the first three energy terms. Gsolvent_p, Gslovent_np, and Gsolvent are the polar and non-polar contributions of the solvent free
energy, and the sum of these two terms (solvent free energy), respectively; G is the free energy of binding (Egas + Gsolvent).
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